Get the Stockscreener App
2.7875
3.62%
0.0975
After Hours:
2.79
0.0025
+0.09%
Intensity Therapeutics Inc stock is traded at $2.7875, with a volume of 4,569.
It is up +3.62% in the last 24 hours and down -15.01% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
See More
Previous Close:
$2.69
Open:
$2.7938
24h Volume:
4,569
Relative Volume:
0.33
Market Cap:
$42.14M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-1.2329
EPS:
-2.261
Net Cash Flow:
$-13.50M
1W Performance:
-5.51%
1M Performance:
-15.01%
6M Performance:
-44.80%
1Y Performance:
+22.80%
1-Day Range:
$2.75
$2.7938
1-Week Range:
$2.50
$3.15
52-Week Range:
$2.1446
$11.44
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
2.7875 | 42.14M | 0 | -16.26M | -13.50M | -2.261 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Intensity Therapeutics Selected for Oral Podium Presentation in - GuruFocus.com
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO - AlphaStreet
Intensity Therapeutics secures $3 million in stock offering By Investing.com - Investing.com South Africa
Medical supplies giant Medline reportedly eyeing $5B IPO in 2025 - MSN
Intensity Therapeutics secures $3 million in stock offering - Investing.com India
Shelton-based Intensity Therapeutics gains $3M investment - Hartford Business Journal
H2G Green Limited Launches Major Rights Issue - MSN
Intensity Therapeutics Raises $3M Through Stock Offering & Warrant Placement | INTS Stock News - StockTitan
Intensity reports promising sarcoma treatment results - Investing.com
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at - StreetInsider.com
Intensity Therapeutics' Cancer Drug Triples Survival Time in Phase 1/2 Sarcoma Trial | INTS Stock News - StockTitan
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - Quantisnow
Q&A: New cancer medication to treat refractory solid tumours - Digital Journal
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nasdaq
3 US Penny Stocks With Market Caps Under $200M To Watch - Simply Wall St
Wednesday, November 13, 2024 - The Auto Channel
IWS Group Holdings to Discuss Interim Results and Dividends - MSN
AstraZeneca Expands U.S. Investment Plan - MSN
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting - The Malaysian Reserve
Intensity Therapeutics to Present Phase 3 Sarcoma Trial Data at CTOS 2024 | INTS Stock News - StockTitan
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - Quantisnow
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - The Manila Times
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
INTSIntensity Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Balancing Decisions Around Breast Cancer Treatment and Fertility, Breastfeeding - Curetoday.com
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - Yahoo Finance
Intensity Therapeutics grants stock options to top executives By Investing.com - Investing.com South Africa
Intensity Therapeutics grants stock options to top executives - Investing.com
High-intensity, low-impact training (HILIT) is gentle on joints and can boost your metabolism. Here’s how to get started - Yahoo Finance
Biliary Tumor Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
SONIRE’s HIFU Therapy System Designated as Breakthrough Device by FDA - BioSpace
SONIRE's HIFU Therapy System Designated as Breakthrough Device by FDA - The Manila Times
Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Thoracic Re-irradiation With Definitive External Beam Radiation Therapy Using Intensity Modulated Radiation Therapy: A Case Report - Cureus
Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer - Curetoday.com
Side Effects, Quality of Life Important to Consider in Breast Cancer Subset - Curetoday.com
There is Nothing Pink About Breast Cancer - Curetoday.com
Head and Neck Cancer Therapeutics Market Overview: Breakthrough Treatments, Technological Innovations, and ... - WhaTech
An Analysis of Ideaya Biosciences Inc (IDYA)’s Potential Price Growth - Knox Daily
Weekly Investment Analysts’ Ratings Changes for Incyte (INCY) - Defense World
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
InvenTrust Properties (NYSE:IVT) Sees Strong Trading Volume - Defense World
Skandinaviska Enskilda Banken AB publ Increases Position in Itron, Inc. (NASDAQ:ITRI) - Defense World
Ideaya Biosciences price target lowered to $52 from $54 at Wedbush - TipRanks
Hoosier Hysterics Podcast: Sisley commits, plus IUWBBs Shay Ciezki and Karoline Striplin - 247Sports
Ideaya Biosciences should be bought on weakness, says Citi - TipRanks
Intapp, Inc. (NASDAQ:INTA) Shares Sold by Hood River Capital Management LLC - MarketBeat
(TIL) Long Term Investment Analysis - Stock Traders Daily
Low-intensity pulsed ultrasound modulates disease progression in the SOD1 - ScienceDirect.com
Itim Group PLC Announces Strong Mid-Year Financials - TipRanks
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):